Incannex wins R&D award for obstructive sleep apnea drug IHL-42X

Incannex Healthcare Inc.

Recognized in Respiratory Disorders category of 2025 Clinical Trials Arena Excellence Awards.
IHL-42X is an oral fixed-dose combination (dronabinol + acetazolamide) for moderate-to-severe OSA.
Award highlights Incannex's research-driven approach to address unmet needs in device-based therapy non-adherence.
CEO Joel Latham states award underscores science-driven approach as IHL-42X advances into late-stage development.
Company also progressing pipeline programs IHL-675A (rheumatoid arthritis) and PSX-001 (anxiety).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.